公开(公告)号：US20240295544A1

公开(公告)日：2024-09-05

申请号：US18022428

申请日：2021-08-24

Applicant: The J. David Gladstone Institutes, a Testamentary Trust Established Under the Will of J. David Glads

Inventor： Todd C. McDevitt ,  Bruce Conklin ,  Melanie Ott ,  Juan Perez-Bermejo ,  Michael Sungwon Kang ,  Sarah Rockwood ,  Camille Simoneau ,  Gokul Ramadoss ,  David Joy

IPC: G01N33/50 ,  C12N5/077 ,  G01N33/68

CPC classification number: G01N33/5061 ,  C12N5/0657 ,  G01N33/5035 ,  G01N33/6887 ,  C12N2503/02 ,  C12N2506/45 ,  C12N2510/00 ,  G01N2333/165

Abstract: Provided herein are methods and compositions useful for identifying compounds that can inhibit SARS-CoV-2 infection or the effects thereof, especially in cardiomyocytes (CMs), which are highly infectible by SARS-CoV-2 corona viruses.

公开(公告)号：US20240192198A1

公开(公告)日：2024-06-13

申请号：US18508058

申请日：2023-11-13

Applicant: Worcester Polytechnic Institute

Inventor： Christina M. Bailey-Hytholt ,  Daniel Zimmer

IPC: G01N33/50 ,  B33Y40/00 ,  B33Y70/00 ,  G01N33/531

CPC classification number: G01N33/5035 ,  B33Y70/00 ,  G01N33/5076 ,  G01N33/531 ,  B33Y40/00

Abstract: This disclosure relates generally to biomimetic proteoliposomes, a method of making and a method of using the same. In particular, this disclosure provides proteoliposomes comprising one or more phospholipid carrier and one or more protein embedded in the one or more phospholipid carrier, wherein the one or more phospholipid carrier comprises a phospholipid composition with similar proportions of phospholipids as a naturally occurring cell type and a phospholipid concentration of about 1-50 mM; and wherein the one or more protein comprises a protein composition with similar proportions of proteins as the naturally occurring cell type.

公开(公告)号：US11981959B2

公开(公告)日：2024-05-14

申请号：US17748522

申请日：2022-05-19

Applicant: MORGAN AND MENDEL GENOMICS, INC. ,  ALBERT EINSTEIN COLLEGE OF MEDICINE

Inventor： Harry Ostrer ,  Johnny C. Loke ,  Ishraq Alim

IPC: G01N31/00 ,  C12Q1/6804 ,  C12Q1/6827 ,  G01N15/14 ,  G01N33/50 ,  G01N33/53 ,  G01N33/574 ,  G01N15/10

CPC classification number: C12Q1/6827 ,  C12Q1/6804 ,  G01N15/14 ,  G01N33/5023 ,  G01N33/5035 ,  G01N33/5041 ,  G01N33/57419 ,  G01N33/57484 ,  G01N2015/1006

Abstract: Heritable pathogenic variants in the mismatch repair (MMR) pathway, also known as Lynch Syndrome (LS), can lead to the development of colon cancer and other cancers. Following mismatch, a complex of proteins consisting of MLH1, MSH2, MSH6 and PMS2 translocate into the nucleus to signal recruitment of repair mechanisms. Flow cytometry-based, functional variant assays (FVAs), were developed to determine whether variants in these MMR repair genes and/or other related genes would augment the nuclear translocation of MLH1 and MSH2 and downstream nuclear phosphorylation of ATM and ATR in response to DNA mismatches. Each assay distinguished pathogenic variants in MMR repair genes (MLH1, MSH2, PMS2 and MSH6) from benign controls. The combination of multiple assays provided robust separation between heterozygous pathogenic variant carriers and benign controls. The ability to produce distinct molecular phenotypes by these assays suggest FVA assays of MMR pathways could be used to identify LS and associated risk of colon and other cancers and could act as an adjunct to MMR gene sequencing panels in categorizing variants.

公开(公告)号：US20240102994A1

公开(公告)日：2024-03-28

申请号：US18039742

申请日：2021-12-03

Applicant: Eisbach Bio GmbH

Inventor： Katharina Sahiri ,  Charlotte Blessing ,  Adrian Schomburg ,  Andreas Ladurner

IPC: G01N33/50 ,  G01N33/58

CPC classification number: G01N33/5035 ,  G01N33/582 ,  G01N2333/91142 ,  G01N2333/914

Abstract: Screening methods as well as kits for identifying compounds capable of trapping proteins, e.g. proteins involved in DNA repair, are provided. The methods provide the use of live-cell imaging and local laser micro-irradiation of nuclear DNA in an assay to measure the effects of compounds on the trapping of 5 proteins on DNA. The disruption, e.g. inhibition, of specific proteins, such as poly-(ADP-ribose) polymerases or ALC1 enzyme, leads to trapping on chromatin and/or at DNA damage sites. This inhibits essential cellular functions, e.g. DNA damage repair, and can potentiate cancer cell killing.

公开(公告)号：US20230330064A1

公开(公告)日：2023-10-19

申请号：US18004821

申请日：2021-07-08

Applicant: Technion Research & Development Foundation Limited ,  RAMBAM MED-TECH LTD.

Inventor： Ido LIVNEH ,  Victoria COHEN-KAPLAN ,  Aaron CIECHANOVER ,  Gilad GOLDHIRSH ,  Yaniv ZOHAR ,  Noa LAVI ,  Bertrand Francois FABRE

IPC: A61K31/405 ,  A61P35/00 ,  A61K31/198 ,  G01N33/50

CPC classification number: A61K31/405 ,  A61P35/00 ,  A61K31/198 ,  G01N33/5035 ,  G01N33/5082

Abstract: The present disclosure provides mTOR agonists that selectively modulate proteasome dynamics, compositions, methods and uses thereof for modulation of stress-induced proteasome dynamics and related pathological conditions. The present disclosure specifically provides therapeutic methods for treating disorders associated with cytosolic accumulation of the proteasome. The invention further provides prognostic methods for detection and monitoring drug resistant cancers, as well as methods for screening for modulators of proteasome dynamics.

公开(公告)号：US20230172944A1

公开(公告)日：2023-06-08

申请号：US17920704

申请日：2021-04-22

Applicant: ATRIVA THERAPEUTICS GMBH

Inventor： Irina KUZNETSOVA, ,  Susanne HEROLD ,  John ZIEBUHR ,  Stephan PLESCHKA ,  Christin PETERANDERL

IPC: A61K31/551 ,  A61P31/16 ,  A61P11/00 ,  G01N33/50

CPC classification number: A61K31/551 ,  A61P31/16 ,  A61P11/00 ,  G01N33/5044 ,  G01N33/5035

Abstract: The present invention relates to a ROCK inhibitor for use in the treatment or prevention of pulmonary edema associated with a virus infection. The present invention further concerns a use of an in vitro test system or the determination of inhibitors effectiveness in preventing or reducing apical sodium-potassium-ATPase (NKA) localisation in lung epithelial cells. Also provided is a method for detecting molecules effective in the prophylaxis and/or treatment of a pulmonary edema. Finally, the invention relates to a test system.

公开(公告)号：US20230160909A1

公开(公告)日：2023-05-25

申请号：US17912337

申请日：2021-03-15

Applicant: UNIVERSITE DE BORDEAUX ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT POLYTECHNIQUE DE BORDEAUX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM

Inventor： Yann PERCHERANCIER ,  Vincent COMPAN ,  Francois RASSENDREN ,  Matthias OLLIVIER ,  Yann CHAPPE

IPC: G01N33/68 ,  G01N33/542 ,  G01N33/50

CPC classification number: G01N33/6872 ,  G01N33/542 ,  G01N33/5035

Abstract: The present invention is directed to a channel fusion subunit comprising an ion conducting channel subunit bound to a probe, wherein the probe comprises an ion sensor bound in between to at least one bioluminescent donor molecule and at least one fluorescent acceptor molecule, wherein the probe is bound to the N-terminal, C-terminal, or within an intracellular or extracellular loop of said channel subunit via either the bioluminescent donor molecule or the fluorescent acceptor molecule, and wherein said bioluminescent donor molecule and fluorescent acceptor molecule are selected so that the emission spectrum of the bioluminescent donor molecule overlaps with the absorbance spectrum of the acceptor molecule, making it possible the non-radiative energy transfer between the bioluminescent energy donor and the fluorescent acceptor through nonradiative dipole-dipole coupling.

公开(公告)号：US09989518B2

公开(公告)日：2018-06-05

申请号：US13389869

申请日：2010-10-08

Applicant: Atsushi Miyawaki ,  Hiroyuki Katayama

Inventor： Atsushi Miyawaki ,  Hiroyuki Katayama

IPC: A61K31/7088 ,  G01N33/50 ,  G01N21/64 ,  G01N21/80

CPC classification number: G01N33/5005 ,  G01N21/6428 ,  G01N21/80 ,  G01N33/5035 ,  G01N2021/6419 ,  G01N2021/6421

Abstract: This invention relates to a method for measuring autophagy in cells, comprising using, as a probe reagent, a single fluorescent protein, to measure a change in fluorescence properties of the fluorescent probe reagent depending on pH changes associated with autophagy, thereby determining the presence or activity of autophagy, wherein the single fluorescent protein is resistant to degrading enzyme activity in the lysosome or vacuole of the cell, it is not denatured or inactivated under acidic to neutral pH environment, and it is capable of changing excitation spectra or fluorescence spectra when located under the environments of acidic region and neutral region.

公开(公告)号：US20180143197A1

公开(公告)日：2018-05-24

申请号：US15517112

申请日：2016-07-11

Applicant: ATOMIC ONCOLOGY PTY LTD

Inventor： George L. Gabor Miklos

IPC: G01N33/574 ,  G01N33/84

CPC classification number: G01N33/574 ,  A61N5/1039 ,  G01N33/4833 ,  G01N33/5035 ,  G01N33/84 ,  G01N2800/52

Abstract: The present invention relates to the generation of an Atomic Therapeutic Indicator (ATI) for a test sample by the quantification of manganese; in voxels of a 3D region of the sample, wherein the 3D region is topographically defined by co-ordinates X′×Y′×Z. The ATI is used to assess the radio-responsiveness i.e. sensitivity or resistance to radiation treatment, of a cancer i.e. a tumour/neoplasm. In a preferred embodiment, the present invention relates to a method of generating the ATI, assessing the radio-responsiveness of a tumour/neoplasm based on the ATI and, based on the assessment, either treating or not treating the tumour with radiation. The present invention also relates to a method of determining if a cancer is likely to reoccur post radiation treatment comprising quantifying the level of manganese in voxels of a 3D region of a test sample from the cancer and determining the frequency of high metallomic regions (HMRs) in the cancer, wherein a high frequency of HMRs is indicative that the cancer is likely to reoccur and a low frequency of HMRs is indicative that the cancer is unlikely to reoccur; and associated methods of treatment.

公开(公告)号：US20180134759A1

公开(公告)日：2018-05-17

申请号：US15654419

申请日：2017-07-19

Applicant: SIGMA-ALDRICH CO. LLC

Inventor： Dmitry Malkov ,  Nathan Zenser ,  Deborah Vassar ,  Fan Zhang ,  Hongyi Zhang

IPC: C07K14/47 ,  G01N33/58 ,  G01N33/50 ,  C12N15/90

CPC classification number: C07K14/4705 ,  C07K2319/60 ,  C07K2319/70 ,  C07K2319/72 ,  C12N15/907 ,  C12N2799/027 ,  G01N33/5035 ,  G01N33/5041 ,  G01N33/582

Abstract: The present disclosure provides a method for endogenously tagging an endogenous protein in a cell, and a cell comprising an endogenously tagged protein. Also described are cells produced using such a method and a kit comprising a cell having tagged endogenous protein.